Functional genetic variants in the vesicular monoamine transporter 1 (VMAT1) modulate emotion processing

Falk W. Lohoff1,*, Rachel Hodge1, Sneha Narasimhan1, Aleksandra Nall1, Thomas N. Ferraro1, Brian J. Mickey2, Mary M. Heitzeg2, Scott A. Langenecker2, Jon-Kar Zubieta2, Ryan Bogdan3,4, Yuliya S. Nikolova3, Emily Drabant5, Ahmad R. Hariri3, Laura Bevilacqua6, David Goldman6, and Glenn A. Doyle1

1Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA
2Department of Psychiatry and Molecular & Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI
3Department of Psychology & Neuroscience, Institute for Genome Sciences & Policy, Duke University, Durham, NC
4Department of Psychology, Washington University in St. Louis, St. Louis, MO
523 and Me, Mountain View, CA
6Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, Rockville, MD

SUMMARY

Emotional behavior is in part heritable and often disrupted in psychopathology. Identification of specific genetic variants that drive this heritability may provide important new insight into molecular and neurobiological mechanisms involved in emotionality. Our results demonstrate that the presynaptic vesicular monoamine transporter 1 (VMAT1) Thr136Ile (rs1390938) polymorphism is functional in vitro, with the Ile allele leading to increased monoamine transport into presynaptic vesicles. Moreover, we show that the Thr136Ile variant predicts differential responses in emotional brain circuits consistent with its effects in vitro. Lastly, deep sequencing of bipolar disorder (BPD) patients and controls identified several rare novel VMAT1 variants. The variant Phe84Ser was only present in individuals with BPD and leads to marked increase monoamine transport in vitro. Taken together, our data show that VMAT1 polymorphisms influence monoamine signaling, the functional response of emotional brain circuits, and risk for psychopathology.
INTRODUCTION

Effective regulation of our emotional responses is critical for normal human behavior and often disrupted in psychopathology. Although key brain regions and circuits, such as the prefrontal cortex (PFC), anterior cingulate cortex (ACC) and the amygdala, have been identified that underlie affective processing, little is known about the underlying molecular mechanisms that contribute to individual differences in the functioning of these circuits. The observed variance in emotional behavior is partly heritable with approximately half of the inter-individual variability attributed to genetic variation. Identification of specific genetic variants that drive this heritability may provide important new insight into molecular and neurobiological mechanisms that shape individual differences in emotional behavior and risk for psychopathology.

Previous research has shown that genetic variation in plasma membrane transporters such as the serotonin, norepinephrine, and dopamine transporters influence inter-individual responses in brain circuits supporting emotional behavior. These transporters are primarily involved in synaptic neurotransmitter reuptake, which contributes to the duration of signaling, but could be considered largely “after the fact.” In contrast, variation in the magnitude of signaling may be more closely related to mechanisms regulating synaptic neurotransmitter release. Despite its importance, the effect of variability in presynaptic monoamine packaging and release on individual differences in human emotional behavior is poorly understood.

Vesicular monoamine transporters (VMATs) package neurotransmitter molecules into presynaptic storage vesicles that release their contents into the synaptic cleft upon arrival of an action potential at the nerve terminal. Two structurally related but pharmacologically distinct VMATs have been identified, encoded by separate genes, VMAT1 (SLC18A1) located on chromosome 8p21 and VMAT2 (SLC18A2) located on chromosome 10q25. Although it was thought initially that only VMAT2 is expressed in brain, expression of VMAT1 in mouse, rat, and human brain has been recently shown. Both genes are differentially expressed in brain during embryonic development. In structure, VMATs are similar in size and molecular topography to other plasma membrane transporters, such as the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET), with 12 transmembrane domains and both tails located in the interior. Nevertheless, VMAT physiology is distinct from plasma membrane transporters in that they use a proton gradient to transport substrates and lack an extracellular compartment. Both proteins are able to transport monoamines; however, they differ in their substrate preferences and affinities. VMAT1 has higher affinity for serotonin, whereas VMAT2 is also able to transport histamine.

Interestingly, no data exist on presynaptic monoaminergic vesicle transport and effects on emotion processing in human; however, indirect evidence suggests that alteration in presynaptic loading of vesicle with catecholamines has an effect on mood states and emotional behavior. For example, reserpine, a non-selective irreversible VMAT inhibitor which causes monoamine depletion and “depressive-like” phenotypes in rodents was introduced in 1954 as an antipsychotic and antihypertensive medication, and was...
instrumental in the development of the “monoamine hypothesis” of affective disorders. However, clinical use of reserpine has been limited due to many drug interactions and side effects, which include lethargy and clinical depression. Consistent with the effects of reserpine, mice lacking VMAT2 die within a few days of birth and heterozygotes for the gene knockout have decreased monoamine levels and increased sensitivity to monoamine neurotoxicity as well as depressive-like phenotypes. Therefore, genetic variation in VMAT1 and/or VMAT2 may contribute to differences in vesicular transport and vesicle filling, which may in turn affect monoaminergic signaling in emotional brain circuits and, subsequently, emotional behavior and risk for psychopathology.

In this paper we focus on VMAT1 which has recently emerged as a candidate gene for neuropsychiatric disorders. Several reports have shown that common missense variants in VMAT1 are associated with bipolar disorder (BPD), schizophrenia (SZ), anxiety-related personality traits and cognitive phenotypes related to SZ. This is remarkable since the VMAT1 gene is located on chromosome 8p, a region previously implicated as a shared genomic susceptibility region for SZ/BPD in linkage scans. The fact that several common missense variations in this gene have been associated with different psychiatric phenotypes suggests that certain fundamental neurobiological mechanisms are shared between psychiatric phenotypes, leading to pleiotropy. This observation has been made for multiple other candidate genes and supports the hypothesis that our current nosology is not reflecting underlying neurobiology.

Here, we used a translational research approach to investigate the neural mechanism underlying emotional behavior modulated by variation in the presynaptic VMAT1 gene using a stepwise approach beginning with identification of a functional locus, namely a common missense variant, and tracing effects of this variant on behavior via two fMRI paradigms in independent samples. We find that Thr136Ile (rs1390938) is functional in vitro, with the Ile- allele leading to increased monoamine transport into presynaptic vesicles. Thr136Ile is shown to cause altered metabolic responses to emotional probes in brain regions implicated in emotional behavior. Furthermore, to assess the potential contribution of rare variation, deep sequencing of BPD patients and controls identified several rare novel VMAT1 variants. A variant Phe84Ser that was exclusively present in individuals with BPD also leads to a marked increase monoamine transport in vitro.

RESULTS

In vitro analyses of common variants

Given previous associations between Thr136Ile genotype and BPD as well as both Thr4Pro and Ser98Thr genotypes with SZ, we used a translational research approach to investigate potential functional effects of these variants. Full length human VMAT1 cDNA is expressed in substantia nigra and was cloned for subsequent experiments (Fig. 1a). VMAT1 protein expression in transfected CV-1 cell lines was quantitated by Western blot and a pharmacological profile consistent with VMAT1 function was revealed in these transfected cells (Fig. 1b, c). We then used site-directed-mutagenesis to transiently transfet cells with constructs representing all haplotypes common in European populations and measured vesicular monoamine transport (Fig. 1d). The Thr-Ser-Ile haplotype containing 136Ile led to

Mol Psychiatry. Author manuscript; available in PMC 2015 January 30.
a 13.3-fold increase in NE uptake, a 2.4-fold increase in DA uptake and a 3.7-fold increase in 5HT uptake as compared to other common haplotypes (Fig. 2), which on the other hand were functionally nearly equivalent. Experiments with stably transfected cell lines showed that 136Ile itself is responsible for the increase in transporter capacity, independent of the background haplotype on which it resides (Supplementary Fig. 1). This variant was associated previously with BPD 27, anxiety-related personality traits 29 and cognitive phenotypes in SZ 28.

Prefrontal Function and VMAT1 Thr136Ile

Given the strong in vitro data for an effect of the Thr136Ile variant on monoamine transport, we tested the effects of Thr136Ile in a single region of interest in the medial prefrontal cortex that was previously shown to activate with negative words 33. For the pooled sample of 85 healthy and 17 major depressive disorder (MDD) subjects, Thr136 homozygotes (n = 63) were more responsive to negative words than Ile136 carriers (n = 39, including 31 Ile136/Ile136 homozygotes and 8 Thr136/Ile136 heterozygotes) after controlling for sex, age, race, and MDD diagnosis (p = 0.008, F1,96 = 7.2, Fig. 3a, b). We then tested an additive genetic model using all three genotype groups (n = 63, 31, and 8) and found a similar result (p = 0.01, β = 0.27, adjusted for gender, self-reported ethnicity and MDD diagnosis. Finally, we explored responses to negative words voxel-wise throughout the brain. No gene effects survived conservative whole-brain correction (p > 0.05, family-wise-error correction), but uncorrected effects of Ile136 genotype were apparent in the task-related medial prefrontal cortex region and adjacent pregenual anterior cingulate cortex (Fig. 3c). There was no effect of Thr4Pro (p=0.38, F=0.78, df=1,97) and Ser98Thr (p=0.52, F=0.43, df=1,97) on medial PFC activation, which converges with previous in vitro results. Finally, based on gene effects on threat-related amygdala activation (see below), we also performed an analysis restricted to bilateral amygdala, which showed no effects of Thr136Ile in the word task (p > 0.05, family-wise-error correction).

Amygdala reactivity and VMAT1 Thr136Ile

To further explore the effects of the Thr136Ile polymorphism on emotion processing, we examined whether Thr136Ile genotype is associated with individual differences in amygdala reactivity to threat. Genotype and neuroimaging data were available from 298 participants who completed the Duke Neurogenetics Study, an ongoing protocol assessing a wide range of behavioral and biological phenotypes among young adult volunteers. Genotypes were imputed for rs1390938 by using SNP rs6992927 which is in complete LD for 174 individuals, whereas direct genotyping of rs1390938 was carried out for 124 subjects. Concordance rates for subjects that we genotyped using both methods was 100%. BOLD fMRI revealed robust bilateral amygdala reactivity across all participants (Fig. 4a). Regression analyses with gender, self-reported ethnicity, and the presence of Axis I or Axis II psychopathology included as covariates revealed a significant effect of Thr136Ile genotype on the overall magnitude of threat-related amygdala reactivity (overall model: F(7,290) = 2.87, p = 0.006, R^2 = 0.065; standardized beta = 0.13, t = 2.25, p = 0.025; change in the overall model after accounting for covariates, ΔF(1,290) = 5.08, ΔR^2 = 0.016). Specifically, Ile136 (i.e., A allele) carriers (n = 121) had heightened left amygdala reactivity relative to Thr136 (i.e., G allele) homozygotes (n = 177; Fig. 4b). Results were similar if
participants were grouped across all 3 resulting genotypes (Supplementary Fig. 2). There was no such genotype effect on overall reactivity of the right amygdala (overall model: \( F(7,290) = 2.10, p = 0.04, R^2 = 0.048; \) Thr136Ile standardized beta = 0.07, \( t = 1.17, p = 0.24 \)). However, in the right (but not left) amygdala, the number of A alleles was marginally associated with reduced amygdala habituation over time (standardized beta = 0.11, \( t = 1.89, p = 0.06; \) Supplementary Fig. 3). Consistent with the in vitro and negative word data described above, there were no effects of Thr4Pro (\( t = 1.39, p = 0.17 \)) or Ser98Thr (\( t = 0.07, p = 0.94 \)) on amygdala reactivity.

**Rare variants in VMAT1 are functional and associated with bipolar disorder**

Given that the common variant Thr136Ile influences negative emotion processing, we then investigated if rare missense VMAT1 variants are functional and are associated with BPD, a phenotype characterized by abnormal affect, recurring depression and mania.

**Sequencing**—DNA Sanger sequencing of BPD patients identified several novel and rare variants (Supplementary Table 1). Interestingly, we found the majority of rare and novel variants in the 5' region of the gene, particularly in exons 2 and 3 that code for the first intravesicular loop (Fig. 5a, b). Comparison of amino acid sequences from different species indicates strong conservation at positions of common and rare variants (Fig. 5b).

Comparison of sequencing results of rare variants in BPD individuals with normal controls from the 1000 Genome project shows that the global burden of rare variants was increased in the BPD group (Supplementary Table 2). Interestingly, several novel variants were only detected in the BPD group but were absent in the controls (Supplementary Table 1).

**In vitro analyses of rare variants**—To investigate whether the rare missense variants have a functional effect on protein transporter function, we assessed monoamine uptake in vitro for Gln10Arg, Phe84Ser, Ala101Pro, Arg138Leu and Leu392Val. Phe84Ser robustly increased monoamine uptake in particular for DA (Fig. 6) and the three variants, Ala101Pro, Arg138Leu and Leu392Val decreased uptake, with Arg138Leu showing the largest effect for dopamine, although similar results were also obtained for 5HT and NE (Fig. 6; Supplementary Fig. 4).

**Genotyping of rare variants**—Because of the robust functional effects of Phe84Ser and Arg138Leu, we genotyped these rare variants in a large sample of BPD cases (n = 4023) and controls (n = 3305) of European descent using standard ABI Taqman “assays by design”. DNA samples were obtained from the NIMH genetics initiative. The Ser84 allele was absent in controls but present in 7 BPD individuals, including one homozygote and 6 heterozygotes (Table 1, Fisher exact test, \( p = 0.009 \)). The Leu138 frequency did not differ statistically between cases and controls (Table 1). Haplotype analysis of the individuals with the rare variant Phe84Ser showed that all subjects had almost exclusively the same haplotype Thr-Ser-Thr, indicative of a common origin and founder population effect \(^{34} \) (Supplementary Table 3).
DISCUSSION

This study was undertaken to determine functional effects of common VMAT1 variants on monoamine signaling, emotional brain circuitry, and risk for psychopathology. In addition, we investigated the functional consequences of rare variants identified through deep sequencing in patients with bipolar disorder. For several decades it has been well-recognized that differences in monoamine neurotransmission contribute to variance in normal behavior, emotionality, and psychopathology. In part, this variation is driven by genetic factors, yet little is known about the identity and neurobiological role of polymorphisms that contribute to this variance. While progress has been made in disentangling these complex phenomena, mostly through imaging genetics approaches that focus on plasma membrane transporters and post-synaptic receptors\(^3\), relatively little is known about presynaptic mechanisms. Such presynaptic components are likely critical as they are a principle common entry point for monoamine homeostasis and may represent a shared pathway for vulnerability to a range of neuropsychiatric phenotypes.

Here, we show that the 136Ile allele of a common VMAT1 genetic polymorphism (rs1390938) leads to increased monoamine transport \textit{in vitro}. To further investigate the functional effects of this “hyperfunction” allele on emotional brain circuitry, we utilized two imaging genetics datasets. In one study, we found that carriers of the VMAT1 “hyperfunction” allele showed diminished hemodynamic responses to negative emotional words in the medial prefrontal cortex and pregenual anterior cingulate cortex when compared to Thr136 homozygotes (\(p = 0.008, F_{1,96} = 7.2\), Fig. 3a, b). These data suggest that the VMAT1 “hyperfunction” allele may predispose certain individuals to a diminished cortical response to negative stimuli. Activity of these prefrontal regions is a critical component of regulating emotional arousal, particularly those triggered by the amygdala in response to environmental stimuli.

In the second imaging genetics study, we examined the effects of rs1390938 on threat-related amygdala reactivity directly. Our results show that the VMAT1 “hyperfunction” allele was associated with increased amygdala reactivity (Fig. 4) and decreased habituation. These patterns are consistent with a number of mood and anxiety disorders including increased reactivity in bipolar disorder during mania\(^35\) and diminished habituation in PTSD\(^36\). Notably, these disorders have also been associated with diminished prefrontal activation as was found with the “hyperfunction” allele in our other imaging genetics study. The laterality of VMAT1 effects on amygdala reactivity (left hemisphere) and habituation (right hemisphere) may reflect the relative contribution of the left and right amygdala to sustained evaluation versus phasic responsiveness to stimuli, respectively\(^37\).

The divergent effects of the “hyperfunction” allele on prefrontal (relatively decreased) and amygdala (relatively increased) suggests that common variation in VMAT1 can have region and task specific effects\(^38,39\). Importantly, these divergent cortical and subcortical effects are consistent with those previously reported for other common polymorphisms resulting in relatively increased monoamine signaling\(^40,41\). Moreover, these divergent effects are consistent with patterns of dysfunction in mood and anxiety disorders characterized by increased amygdala reactivity and decreased prefrontal activity\(^42\). Thus, the results of our
imaging genetics studies suggest that the 136Ile allele is associated with a pattern of dysfunctional prefrontal and amygdala function that may predispose carriers to the development of mood and anxiety disorders. Studies are now needed to directly evaluate the impact of the 136Ile allele on corticolimbic circuit function in mood and anxiety disorders as well as on the structural and functional connectivity of this circuit during explicit emotion regulation and fear learning tasks, which directly engage this circuitry.

It should be noted that the majority of subjects in our two imaging genetics studies were healthy individuals; however, impaired social cognition and emotion processing are hallmarks of several psychiatric disorders such as SZ and BPD. In fact, the Thr136Ile variant was recently shown to be associated with several cognitive phenotypes in schizophrenia and anxiety-related personality traits. Other SNPs that are in LD with Thr136Ile (rs1390938) have been associated with major depression and anorexia nervosa. The association of the functional Thr136Ile SNP with several other psychiatric phenotypes suggests that this VMAT1 variant might influence brain circuits involved in emotion processing, which are shared by several psychiatric disorders but not disease per se. In line with this hypothesis is the observation that although the Thr136Ile polymorphism was previously shown to be associated with BPD, with the 136Ile being more common in the control population, subsequent GWAS failed to establish a strong relationship between rs1390938 and disease. This lack of replication could be due to the complex mode of inheritance, complex LD structure resulting in imperfect r2 diluting signal detection, and/or clinical heterogeneity. Extensive subphenotyping including endophenotypic measures as well as subanalyses of patients with linkage signals to chromosome 8p might strengthen the power to detect an effect of Thr136Ile on disease risk in future studies.

Although GWAS failed to identify VMAT1 as a major susceptibility gene for BPD, due to the above mentioned reasons, we conducted deep sequencing to identify rare variants possibly associated with disease. Sequencing detected several rare missense variants in BPD patients (Fig. 5). Interestingly, most of these novel rare variants are located in the first intravesicular loop of VMAT1, a region that has been implicated in regulating transport of neurotransmitter in to vesicles. In fact, our in vitro analyses of the rare variant Ser84 and the common allele Ile136 show that these alleles lead to increased vesicle filling (Fig. 2; Fig. 6; Supplementary Fig. 1) whereas the rare Leu138 variant leads to decreased vesicle filling of monoamines (Fig. 6). Association analyses of the rare variants Phe84Ser and Arg138Leu in 4023 BPD patients and 3305 controls show that the Ser84 allele was only present in BPD individuals but absent in controls (Table 1). Given that Thr136Ile leads to increased monoamine transport and has an effect on inter-individual responses to mPFC activation of negative words and threat-related amygdala reactivity, the rare Phe84Ser variant may have similar effect on these brain circuits. Due to the low prevalence of the Ser84 allele, imaging genetics studies are not feasible at this point. Although it is unknown how large such an effect of this rare VMAT1 variant will be in individuals with BPD, we speculate that rare variants might have larger effects on function. Future studies are needed to comprehensively investigate SNP-dosage effects on transporter function in vivo.

In summary, we show that the common Thr136Ile and rare Phe84Ser variant are located in close proximity to a regulatory region within the VMAT1 gene and lead to hyperfunction of
vesicular transport \textit{in vitro}. Thr136Ile (rs1390938) has an effect on inter-individual responses to emotion processing \textit{in vivo} in two separate fMRI paradigms, providing insight into a mechanism for how genetic variation in presynaptic vesicular transport of monoamines can influence emotionality. Although emotion responding is critical for normal adaptive behavior, it is clear that inter-individual variance exists, with extremes often observed in psychopathology. Our study provides convergent neurobiological evidence for a role of both rare and common VMAT1 variants in neural emotion processing and related psychopathology and advances our understanding of the complex mechanisms regulating monoaminergic signaling and emotional behavior.

\section*{METHODS}

\textbf{In vitro assays}

\textbf{Plasmid Construction and Mutagenesis—}The coding sequence of the human VMAT1 gene (\textit{SLC18A1}) was amplified from commercially available cDNA extracted from postmortem human substantia nigra tissue (ClonTech, Mountain View, CA)(Fig. 1b). ExPand High Fidelity polymerase (Roche) and 1M betaine were used in the polymerase chain reaction (PCR) cocktail with forward (5'-CCT CCC TTC CA-3') and reverse (5'-GAT TCC CAG GCA GA-3') primers. The thermocycling protocol was as follows: 94°C for 5 minutes followed by 40 cycles of 94 °C for 1 minute, 60 °C for 1 minute, and 72 °C for 2 minutes. The final extension was 72 °C for 5 minutes. PCR product was directly T/A cloned into Vector (TOPO TA Cloning® Kit, Invitrogen). \textit{SLC18A1} cDNA was released from the \textit{pCR®II-TOPO®} vector by XhoI and BamHI digest. BamHI-VMAT1-XhoI cDNAs were then ligated into pcDNA5/FRT that had been digested with BamHI and XhoI.

Sanger sequencing revealed our initial clone contained \textit{SLC18A1} cDNA encoding the VMAT1 protein isoform with threonines at amino acid positions 4, 98, and 136 (Thr-Thr-Thr isoform). Site-directed mutagenesis (QuikChange, Stratagene) was used to create VMAT1 isoforms with common haplotypes and rare variants (Supplementary Table 4). The thermocycling protocol for all site-directed mutagenesis reactions was as follows: 95°C for 30 seconds followed by 12 cycles of 95°C for 30 seconds, 60°C for 1 minute, and 68°C for 8 minutes. The final extension was 68°C for 7 minutes. Mutated \textit{SLC18A1} plasmid amplicons were treated with DpnI, transformed into competent XL1-Blue \textit{E. coli}, and the plasmid DNA of various clones prepared and VMAT1 fully sequenced by Sanger sequencing to ensure the absence of unwanted mutations prior to being used in subsequent \textit{in vitro} analyses.

\textbf{Transfections—}Empty pcDNA5/FRT vector or pcDNA5/FRT-VMAT1 constructs were co-transfected with pOG44 into Flp-in CV-1 (Invitrogen) cells using Lipofectamine 2000 and Plus reagent (Invitrogen), according to the manufacturer’s recommendations. Stable VMAT1-expressing clones (Pro4-Thr98-Thr136, Thr4-Ser98-Thr136, Thr4-Thr98-Thr136 or Thr4-Thr98-Ile136) were selected by addition of hygromycin to the growth medium and clonal colonies were then isolated and expanded for further analysis. For transient transfections, Flp-in CV-1 cells (4×10^4) were transfected with 0.5 \mu g human VMAT1
construct, pcDNA5/FRT or no DNA (mock) using the TransIT-LT1 Transfection Reagent (Mirus Corp.; Madison, WI).

**hVMAT1 Expression Analysis (Immunoblots)**—Flp-in CV-1 cells stably transfected with human VMAT1 constructs Pro4-Thr98-Thr136, Thr4-Ser98-Thr136 or Thr4-Thr98-Ile136 (Fig. 1b) were washed twice with 1 mL PBS and 0.25 mL Trypsin 0.05% EDTA was added to disassociate cells from the plate. Trypsinization was stopped with the addition of 0.5 mL DMEM (completed with 10% FBS and 0.1% PenStrep). Cells were centrifuged at 500g for 5 minutes at 4°C, medium was removed, and pellets were washed three times with PBS. After washing, cells were lysed on ice in 300 μL Triton X-100 lysis buffer for 15 minutes on ice and centrifuged at 2500g for 10 minutes at 4°C to remove nuclei and cellular debris. Total soluble protein was quantified using the BCA Protein Assay (Pierce; Rockford, Ill) and a BioTek Instruments μQuant Spectrophotometer. To determine VMAT1 expression levels from stable cell lines, 50 μg of isolated protein was heated at 70°C for 10 minutes in the presence of 1x NuPAGE® LDS Sample Buffer and Sample Reducing Agent (Invitrogen). Prestained SDS-PAGE broad range standards (Bio-Rad) were used as a sizing ladder. Proteins were separated by electrophoresis at 200 V for 50 minutes on a NuPAGE® Novex 10% Bis-Tris gel in 1x NuPAGE® MOPS SDS Running Buffer and Antioxidant (Invitrogen), electrophoretically transferred to a nitrocellulose membrane at 30 V for 90 minutes in 1x NuPAGE® Transfer Buffer and Antioxidant (Invitrogen). Membranes were blocked for two hours in 10% nonfat dry milk. Blocked membranes were immunoblotted with primary antibody SC-7718 (Santa Cruz) at a dilution of 1:300 for 48 hours. Blots were then washed once with 200 mL 1x Tris-buffered saline with 0.1% Tween-20 (TBS-T) for 15 minutes and three times with 50 mL 1x TBS-T. Bound primary antibody was detected by incubation for one hour with a horseradish peroxidase-conjugated anti-goat secondary antibody at a 1:10,000 dilution. Chemiluminescence was generated by incubating membranes with an ECL Plus Western Blotting Detection Kit (Amersham Biosciences) and blots were then exposed to HyBlot CL film (Denville Scientific) for various times. (Fig. 1b) Primary and secondary antibodies were stripped from the membranes using Restore™ Western Blot Stripping Buffer (Pierce), washed twice in 50 mL 1x TBS-T for five minutes, and membranes were again blocked overnight in 10% nonfat dry milk. Blocked membranes were probed for β-actin with primary antibody MAB 1501 (Millipore) at a dilution of 1:1,000 for 1 hour. Blots were then washed once with 200 mL 1x TBS-T for 15 minutes and three times with 50 mL 1x TBS-T. Bound primary antibody was detected by incubation for 30 minutes with a horseradish peroxidase-conjugated anti-mouse secondary antibody at a 1:10,000 dilution. Chemiluminescence was generated and blots exposed to film as described above.

To determine VMAT1 expression levels in Flp-in CV-1 cells transiently transfected with human VMAT1 constructs used in the uptake assays, 3 μg of total protein isolated from transfected cells were heated at 70°C for 10 minutes in the presence of 1x NuPAGE® LDS Sample Buffer and Sample Reducing Agent (Invitrogen). Prestained Novex Sharp Protein standards (Invitrogen) were used as a sizing ladder. Proteins were separated by electrophoresis at 200 V for 1 hour on a NuPAGE® Novex 4–12% Bis-Tris gel in 1x NuPAGE® MOPS SDS Running Buffer and Antioxidant (Invitrogen), electrophoretically separated.
transferred to a nitrocellulose membrane using Invitrogen’s iBlot Dry Blotting System. Membranes were blocked overnight in 10% nonfat dry milk. Blocked membranes were immunoblotted with primary antibody SC-7718 (Santa Cruz) at a dilution of 1:500 for 48 hours. Blots were then washed once with 200 mL 1x TBS-T for 15 minutes and three times with 50 mL 1x TBS-T. Bound primary antibody was detected by incubation for one hour with a horseradish peroxidase-conjugated anti-goat secondary antibody at a 1:10,000 dilution. Chemiluminescence was generated and blots exposed to film as described above. Primary and secondary antibodies were stripped from the membranes using ReBlot Plus Strong Antibody Stripping Solution (Millipore), washed twice in 50 mL 1x TBS-T for five minutes, and membranes were again blocked overnight in 10% nonfat dry milk. Blocked membranes were probed for β-actin with primary antibody MAB 1501 (Millipore) at a dilution of 1:1,000 for 1 hour. Blots were then washed once with 200 mL 1x TBS-T for 15 minutes and three times with 50 mL 1x TBS-T. Bound primary antibody was detected by incubation for 30 minutes with a horseradish peroxidase-conjugated anti-mouse secondary antibody at a 1:10,000 dilution. Chemiluminescence was generated and blots exposed to film as described above.

**Pharmacological analysis**—Flp-in CV-1 cells stably expressing the Thr-Thr-Ile VMAT1 isoform were used to verify the pharmacological characteristics of the protein. [3H]5-HT was used in a modified monoamine uptake assay. The [3H]monoamine uptake protocol (see below) was modified such that prior to addition of the [3H]5-HT, digitonin permeabilized cells were pre-incubated with reserpine or tetrabenazine at various concentrations in uptake buffer (Fig. 1c).

**[3H]Monoamine Uptake**—Monoamine uptake was performed with a protocol similar to those used in previous studies 49, 50. For analysis of common haplotypes and rare variants, Flp-in CV-1 cells were plated in 24 well Bio-Coat Type I Collagen plates. Cells (4×10⁴) were transiently transfected with 0.5 μg human VMAT1 constructs using the TransIT-LT1 Transfection Reagent (Mirus Corp.; Madison, WI). After 48 hours, cells were washed in 1 mL room temperature Phosphate-buffered saline (PBS) containing MgCl₂ and CaCl₂, then incubated in 1 mL uptake buffer (110 mM potassium tartrate, 5 mM glucose, 0.2% BSA, 200 μM calcium chloride, 1 mM ascorbic acid, 1 μM Pargyline, 25 mM HEPES) for 5 minutes at room temperature. Cells were then incubated in uptake buffer with 10 μM Digitonin at 37°C for ten minutes, followed by an 10 minute incubation in 0.5 mL uptake buffer containing 5 mM MgATP and ~0.1 μM [3H]-labeled monoamine. Cells were then placed on ice and washed once with 1 mL ice-cold uptake buffer for 1 minute and twice with ice-cold 1 mL PBS containing MgCl₂ and CaCl₂ for 1 minute. After washing, cells were solubilized in 0.5 mL 1% SDS at room temperature, transferred to scintillation vials, and 10 mL Eco-Lite Scintillation Fluid was added. Samples were shaken and incubated in the dark for 30 minutes before counting with a Wallac 1209 Rackbeta Liquid Scintillation Counter. Counts per minute were recorded for each sample and used to calculate the fmol amount of [3H]-labeled monoamine taken up per well. All experiments were carried out at least 4 times in triplicates.

*Mol Psychiatry. Author manuscript; available in PMC 2015 January 30.*
VMAT1 expression was determined by immunoblotting (see above). Prior to uptake assay analysis, two wells (duplicates) containing Flp-in CV-1 cells transiently transfected with the same TransIT-LT1:DNA complexes as the uptake assay cells were washed twice with 1 mL PBS and 0.25 mL Trypsin 0.05% EDTA was added to disassociate cells from the Bio-Coat Type I Collagen plates. Trypsinization was stopped with the addition of 0.5 mL DMEM (completed with 10% FBS and 0.1% PenStrep). Cells were centrifuged at 500 g for 5 minutes at 4°C, medium was removed, and pellets were washed three times with 50 μL PBS. After washing, cells were lysed on ice in 20 μL Igepal CA-630 non-denaturing lysis solution for 15 minutes and centrifuged at 2500 g for 10 minutes at 4°C to remove nuclei and cellular debris. Total protein was quantified using the Pierce BCA Protein Assay and a BioTek Instruments μQuant Spectrophotometer. Optical densities for VMAT1 and β-actin proteins detected by immunoblotting (see above) were determined using ImageJ and VMAT1 values were normalized using β-actin values as a loading control. VMAT1 expression normalized to β-actin was then used to normalize [3H]-labeled monoamine uptake values determined in parallel in transiently transfected cells (see above). To confirm the result of transient uptake assays for the Thr136Ile variant using the above methods, [3H]monoamine uptake assays using cell lines stably transfected with either Thr4-Thr98-Thr136 or Thr4-Thr98-Ile136 were also carried out (Supplementary Fig. 1). Experiments were repeated at least 4 times in triplicates.

fMRI Emotion Word Task and VMAT1 Thr136Ile

The VMAT1 variant Thr136Ile was genotyped from whole blood using ABI Taqman methodology as described above (rs1390938, major allele G = Thr, minor allele A = Ile).

Subjects—Procedures were approved by the Institutional Review Board at the University of Michigan, and all participants gave written informed consent. Participants were recruited through local advertisement for neuroimaging studies of pain processing and major depressive disorder (MDD), as described previously. Healthy subjects were screened to exclude major medical illness, psychiatric disorder, or substance use disorder. Subjects with MDD were diagnosed with a current moderate-to-severe depressive episode using the Structured Clinical Interview for DSM-IV, administered by an experienced psychiatric research nurse, and diagnosis was confirmed with a clinical interview by a psychiatrist. Comorbid generalized anxiety disorder, social anxiety disorder, or specific phobia was permitted, but major medical illness and other axis I diagnoses were otherwise excluded. All participants were fluent English speakers, and all participants but one were right-handed. All subjects were free of exogenous hormones or medications with central nervous system activity, and they were instructed to abstain from use of all psychoactive substances for 24 hours prior to the study. fMRI data were available from 93 healthy participants and 20 MDD subjects. Of those 113 subjects, 103 provided blood for genotyping (85 healthy and 18 MDD), and genotyping was successful in 102 subjects. Fifty-one (50%) were female, and the mean age was 30 yr (SD = 10 yr, range = 20–58 yr). Self-reported race was Caucasian (n=72), African American (n=17), Asian (n=5), or other/mixed (n=8).

Emotion word task—Subjects performed an affective word task during which they silently read emotionally valenced words, as described previously. Words were
selected from the Affective Norms for English Words list which provides normative emotional ratings for valence (negative to positive, 1 to 9) and arousal (low to high, 1 to 9)\textsuperscript{53}. We used negative words with valence ratings less than 3, neutral words with valence ratings between 4.5 and 5.5, and positive words with valence ratings greater than 7. Arousal ratings were greater than 5 for positive and negative words (not significantly different from each other), and greater than 2 for neutral words. Nine participants viewed a list of investigational negative, positive, and neutral words that lacked normative ratings, but analyses demonstrated no differences in activation, so they were pooled together. Words were presented on screen for 3 s each, separated by 1 s of fixation, in blocks of 6 words (E-Prime version 1.1, Psychology Software Tools Inc., Pittsburgh PA). Participants pressed a button after silently reading each word. With the exception of seven individuals whose behavioral data were corrupted after the experiment, we confirmed that response rates were greater than 90\% for all participants. The block design incorporated 24-second blocks of positive, negative, or neutral words separated by 18-second rest periods. Subjects were instructed to rest while viewing crosshairs during the rest periods. Each session included 6 blocks, counterbalanced by emotional valence using a Latin squares design, and each subject completed three runs. Subjects with usable data from at least two runs were included in analyses.

**Magnetic resonance imaging**—As previously described\textsuperscript{33,51}, the blood oxygenation level dependent (BOLD) signal was measured in the whole brain using a General Electric Signa 3-Telsa scanner (Milwaukee WI) with a standard radiofrequency coil, using a T2*-weighted pulse sequence (spiral in/out, gradient echo; TR = 2 s; TE = 30 ms; FA = 90\textdegree; FOV = 20 or 24 cm; 64-by-64 image matrix; slice thickness = 3 or 4 mm; 30 oblique-axial slices). A high-resolution T1-weighted scan was also acquired for anatomical localization (3-dimensional spoiled gradient recalled echo; TR = 25 ms; min TE; FOV = 24 cm; 256-by-256 matrix; slice thickness = 1.4 mm). Head motion was minimized by use of foam pads. Data were reconstructed off-line, de-spiked, slice-time corrected, realigned, and co-registered. Images from each session were visually inspected for artifacts and screened for excessive head movement (more than 2 mm of translation or 2 degrees of rotation). Functional images were smoothed with a Gaussian kernel (full width at half maximum, 6 mm) to reduce residual noise and inter-individual variability and resampled at 2×2×2 mm.

**Statistical analysis**—BOLD responses were modeled with SPM2 (Wellcome Department of Cognitive Neurology, University College London, UK) using a general linear model and canonical hemodynamic response function, as described previously\textsuperscript{33}. Analysis proceeded in two stages. In the first level, activation maps were derived for individual subjects, including task-related covariates of interest and nuisance covariates (head translation and rotation). To allow comparisons across individuals, regressor and contrast images were spatially normalized by warping each subject’s T1 image to standard stereotactic space (Montreal Neurological Institute, MNI) using the SPM2 nonlinear algorithm, and applying that transformation to contrast images. In the second level, a random effects analysis was employed to determine average task and group effects. A mask excluded the cerebellum and brainstem below the midbrain because these regions were not well represented. Task effects were determined for two primary contrasts of interest, negative–neutral words and positive–
neutral words, which isolated affective processing and controlled for non-specific lexical and visual processing. As described previously, among 93 healthy participants, the negative–neutral contrast activated a cluster in the medial prefrontal cortex (peak coordinates = −2, 56, 22; peak z = 4.3; cluster size = 2184 mm$^3$ at one-tailed p<0.001; family-wise-error cluster corrected p = 0.04). This single task-related region of interest was used for hypothesis testing. (No significant activation was found for the positive–neutral contrast.) The average percent signal change in the region of interest was computed from regressor images for each subject and analyzed outside of SPM. To test the primary hypothesis that the VMAT1 Thr136Ile polymorphism affects medial prefrontal cortex responses to negative words, percent signal change in the region of interest was compared between Thr136 homozygotes (n = 63) and Ile136 carriers (n = 39). Initial power analyses indicated that, with group sizes of 63 and 39, we would have 80–90% power to detect a standardized effect size of 0.3 with a 5% two-tailed type I error rate. Percent signal change was entered as the dependent variable and Ile136 carrier status as the between-subjects factor in a univariate general linear model (PASW Statistics 18.0, SPSS Inc., Chicago IL). Covariates sex, age, Caucasian race, and MDD diagnosis were included in the model as potential confounders. Exploratory analyses were performed after hypothesis testing. To test an additive genetic model, we used linear regression (PASW Statistics 18.0) with the three genotype groups (Ile/Ile, Ile/Thr, and Thr/Thr) coded 1, 2, and 3, respectively, controlling for sex, age, Caucasian race, and MDD diagnosis. To explore gene effects elsewhere in the brain, we performed a voxel-wise analysis in SPM8 using an ANOVA model with two groups (Thr136 homozygotes and Ile136 carriers) and with sex, age, Caucasian race, and MDD diagnosis as covariates. Spatial coordinates are reported in MNI space.

In contrast to threat-related facial stimuli, this task does not generally engage the amygdala. However, based on observed genetic effects on threat-related amygdala activation, we examined gene effects on amygdala activation in the Emotion Word Task. SPM8 family-wise-error correction was applied within a bilateral amygdala mask, defined anatomically based on the Talairach atlas as implemented in the Wake Forest University PickAtlas Toolbox.

**fMRI amygdala reactivity task and VMAT1 Thr136Ile**

**Duke Neurogenetics Study**—Genotype (rs1390938 within *SLC18A1*; A/G) and neuroimaging data were available from 298 participants who completed the Duke Neurogenetics Study, an ongoing protocol assessing a wide range of behavioral and biological phenotypes among young adult volunteers. Participants completed an archival challenge paradigm, which robustly elicits threat-related amygdala reactivity. The paradigm consists of four task blocks wherein participants match face stimuli with angry, fearful, surprised, or neutral expressions - all of which convey threat-related information - interleaved with 5 sensorimotor control blocks of matching simple geometric shapes. Regression analyses with gender, self-reported ethnicity, and psychopathology as covariates were used to test the association between rs1390938 genotype and threat-related amygdala reactivity.
Participants—All participants (n = 350) provided informed consent in accord with the guidelines of the Duke University Medical Center Institutional Review Board, and were in good general health. Study exclusions included: 1) medical diagnoses of cancer, stroke, diabetes requiring insulin treatment, chronic kidney or liver disease, or lifetime history of psychotic symptoms; 2) use of psychotropic, glucocorticoid, or hypolipidemic medication; and 3) conditions affecting cerebral blood flow and metabolism (e.g., hypertension). Current DSM-IV Axis I and select Axis II disorders (Antisocial Personality Disorder and Borderline Personality Disorder) were assessed with the electronic Mini International Neuropsychiatric Interview and Structured Clinical Interview for the DSM-IV (SCID) subtests, respectively. These disorders were not exclusionary as the DNS seeks to establish broad variability in multiple behavioral phenotypes related to psychopathology. A total of 52 participants from the initial sample were excluded due to: insufficient DNA yield (n = 2), scanner artifacts in fMRI data (n = 3), incidental structural brain abnormalities (n = 3), a large number of movement outliers in fMRI data (n = 5; see ART description below), inadequate signal in our amygdala regions of interest (n = 4), and poor behavioral performance (n = 35; accuracy lower than 75%). Thus, all data analyses were conducted in a final sample of 298 (see Supplementary Table 5).

Amygdala Reactivity Task—In our threat-related amygdala reactivity paradigm, participants complete 4 blocks of a perceptual face-matching task interleaved with five blocks of a sensorimotor control task. In each face-matching trial, participants view a trio of faces (expressing angry, fearful, surprised or neutral emotions) and select which 1 of 2 faces (displayed on the bottom) is identical to the target stimulus (displayed on top). Each block has 6 trials (balanced for gender) containing stimuli derived from a standard set of facial affect pictures. Blocks are emotion-specific (e.g., in the fearful block participants see only faces expressing fear) and block order is pseudo-randomized across participants. Each face trio is displayed for 4 seconds with a variable inter-stimulus interval of 2–6 seconds (mean = 4 seconds) between presentations, for a total block length of 48 seconds. In the sensorimotor control task participants view a trio of geometric shapes (circles, horizontal ellipses, vertical ellipses) and select which 1 of 2 shapes (displayed on the bottom) is identical to the target shape (displayed on top). Each sensorimotor block consists of 6 different shape trios that are displayed for 4 seconds with a fixed inter-stimulus interval of 2 seconds between presentations, for a total block length of 36 seconds. All blocks are preceded by a brief instruction (“Match Shapes” or “Match Faces”) and the total paradigm length is 390 seconds. Reaction times and accuracy are recorded from an MR-compatible button-box.

Genotyping—Genotyping for 174 participants was conducted by 23andMe. Briefly, genomic DNA from all participants was isolated from buccal cells derived from Oragene DNA self-collection kits (DNA Genotek, Inc., Kanata, Ontario, Canada) customized for 23andMe. DNA extraction and genotyping were performed by the National Genetics Institute (NGI), a CLIA-certified clinical laboratory and subsidiary of Laboratory Corporation of America. The Illumina Omni Express chip and a custom array containing an additional ~300,000 SNPs were used to provide genome-wide data (Tung, Do, Erikkson). Because genotyping for rs1390938 failed on this array, we extracted data for rs6992927, which is in complete LD with rs1390938. An additional 124 participants were directly
genotyped for rs1390938 by our team using ABI TaqMan genotyping methods as described above. Of the 298 participants included in the study, 28 were genotyped by both 23andMe and our team; there was 100% genotyping concordance. Genotypes in our sample did not differ significantly from Hardy-Weinberg equilibrium (p = 0.76).

**BOLD fMRI data acquisition**—Participants were scanned using a research-dedicated GE MR750 3T scanner equipped with high-power high-duty-cycle 50-mT/m gradients at 200 T/m/s slew rate, and an eight-channel head coil for parallel imaging at high bandwidth up to 1MHz at the Duke-UNC Brain Imaging and Analysis Center. A semi-automated high-order shimming program was used to ensure global field homogeneity. A series of 34 interleaved axial functional slices aligned with the anterior commissure-posterior commissure (AC-PC) plane were acquired for full-brain coverage using an inverse-spiral pulse sequence to reduce susceptibility artifact (TR/TE/flip angle=2000 ms/30 ms/60; FOV=240 mm; 3.75x3.75x4 mm voxels; interslice skip=0). Four initial RF excitations were performed (and discarded) to achieve steady-state equilibrium. To allow for spatial registration of each participant’s data to a standard coordinate system, high-resolution three-dimensional structural images were acquired in 34 axial slices coplanar with the functional scans (TR/TE/flip angle=7.7 s/3.0 ms/12; voxel size=0.9x0.9x4 mm; FOV=240 mm, interslice skip=0).

**BOLD fMRI data analysis**—The general linear model of SPM8 (http://www.fil.ion.ucl.ac.uk/spm) was used for whole-brain image analysis. Individual subject data were realigned to the first volume in the time series to correct for head motion before being spatially normalized into the standard stereotactic space of the Montreal Neurological Institute template using a 12-parameter affine model. Data were then smoothed to minimize noise and residual differences in individual anatomy with a 6mm FWHM Gaussian filter. Next, the ARtifact detection Tool (ART) was used to generate regressors accounting for the possible confounding effects of volumes with large motion deflections (i.e., >0.6mm relative to the previous time frame) or spiking artifacts (i.e., global mean intensity 2.5 standard deviations from the entire time series). Five participants, who had more than 5% of their acquisition volumes flagged by ART, were dropped from analyses.

Following preprocessing, linear contrasts employing canonical hemodynamic response functions were used to estimate task-specific (i.e., Faces > Shapes) BOLD responses for each individual. Individual contrast images (i.e., weighted sum of the beta images) were then used in second-level random effects models accounting for scan-to-scan and participant-to-participant variability to determine mean task-specific regional responses using one-sample t-tests. A voxel-level statistical threshold of p<.05, FWE corrected for multiple comparisons across the amygdala regions of interest, and a cluster-level extent threshold of 10 contiguous voxels was applied to this analysis. Our bilateral amygdala regions of interest (ROIs) were created from the Automated Anatomical Labeling (AAL) atlas using the Wake Forest University PickAtlas toolbox in SPM8. Because of the potential for signal loss and noise often observed in the amygdala and adjacent regions, single-subject BOLD fMRI data were included in subsequent analyses only if there was a minimum of 90% signal coverage in the amygdala ROIs. Four participants had less than 90% coverage and were dropped from analyses.

*Mol Psychiatry*. Author manuscript; available in PMC 2015 January 30.
BOLD parameter estimates from the maximal voxels within the right and left amygdala clusters exhibiting main effects of task were extracted using the VOI tool in SPM8 and exported for regression analyses in SPSS (v.18). Extracting parameter estimates from maximal voxels activated by our fMRI paradigm, rather than voxels specifically correlated with our independent variables of interest, precludes the possibility of any correlation coefficient inflation that may result when an explanatory covariate is used to select a region of interest. We have used this more conservative analytic strategy in recent studies 57. Gender, self-reported ethnicity (dummy coded as Caucasian/Not Caucasian, African American/Not African American, Asian/Not Asian, Latino/Not Latino, and Other/Not Other), and the presence of an Axis I or Axis II disorder were included as covariates in all analyses.

**DNA Sequencing**

The VMAT1 (SLC18A1) gene is located on chromosome 8, 20,046,660 – 20,084,906bp (genome.ucsc.edu). It consists of 16 exons spanning 38,346bp that encodes 525 amino acids (NM_003053; www.ncbi.nlm.nih.gov). DNA samples from Bipolar Disorder (BPD) type I patients, as diagnosed by DSM-IV criteria, were obtained from the National Institute of Mental Health (NIMH) Genetics Initiative on BPD (www.nimhgenetics.org). Sanger sequencing of all VMAT1 exons was carried out in 196 BDP individuals, except for exon 2 and 3 for which 390 BPD and 196 Caucasian controls were sequenced. The VMAT1 gene exons and exon-intron boundaries were sequenced using exon-specific primers (Supplementary Table 6). hVMAT1 custom-DNA-oligomers (Integrated DNA Technologies (IDT), San Jose, CA) were designed for each exon using the Primer Select feature on the IDT website. Primer solutions of 0.1mM were prepared by adding appropriate amount of dH2O to the lyophilized primer pellet provided. The primer solutions were diluted ten-fold to prepare working stock solutions used in PCRs. A standard PCR was used to amplify each exonic region separately. Each PCR was comprised of a cocktail of 2.5μL GeneAmp® 10X buffer containing 15mM MgCl2 (ABI, Foster City, CA), 1μL GeneAmp® dNTP mix (ABI, Foster City, CA), 1μL each of forward and reverse primers, 0.25μL of AmpliTaq® DNA polymerase (5U/μl; ABI, Foster City, CA), 20.25μL of dH2O, and 1μL of 10ng/μL DNA. The PCR was then run according to the following protocol (Supplementary Table 6): 95°C hold for 5 min, followed by 35 cycles of 95°C for 30 sec, annealing temperature for 30 sec, and 72°C for 1 min, then a 72°C hold for 7 min followed by a 4°C hold. The PCR product was verified by gel electrophoresis by running 10μL of product and 2μL 6X loading dye (Sigma-Aldrich) on a 2% agarose gel stained with ethidium bromide. DNA bands were visualized using TransUV light waves and were checked for appropriate band size against a ΦX174 DNA/HaeIII Marker (Promega, Madison, WI). The PCR products were then prepared for Sanger sequencing by degrading primers and dephosphorylating excess nucleotides using Exo-SapIT® (Affymetrix, Santa Clara, CA) as follows. 2μL Exo-SAPIT was added to 10μL of PCR product and treated under the following conditions in a thermal cycler: 37°C hold for 20 min and 80°C hold for 20 min. Samples were sequenced by big-dye termination chemistry Sanger sequencing at the Nucleic Acid/PCR core (NAPcore) facility at the Joseph Stokes Jr. Research Institute (see http://www.research.chop.edu/cores/napcore/index.php for further details). Sequencing reactions were prepared using 10ng DNA per 100bp sequence, 2 picomole primer (1μL of 2μM) and quantity sufficient dH2O to achieve
18 μL total volume. Sequencing results were analyzed with the Sequencher® program (Gene Codes Corporation, Ann Arbor, MI) to detect SNPs. All SNPs found with this program were confirmed through a new PCR and re-sequencing of the sample in which the variant was found.

Genotyping

Genotyping of the functional rare variants Phe84Ser (rs17215801) and Arg138Leu (rs148468662) was performed in BPD patients (n=4023) and normal controls (n=3305) of European descent from the NIMH Genetic Initiative (www.nimhgenetics.org) using standard ABI TaqMan genotyping protocols. For each SNP, a custom TaqMan allelic discrimination assay was designed and ordered using the FileBuilder 3.1 software (ABI, Life Technologies). Quality control was assured by including DNA of probands with rare variants confirmed by sequencing as positive controls. Results were imported into TaqMan Genotyper™ software for quality control and final analysis. All individuals with a rare variant allele were confirmed by Sanger sequencing. Genotyping of the common variants Thr4Pro (rs2270641), Ser98Thr (rs2270637) and Thr136Ile (rs1390938) in the human imaging dataset (see below) was carried out using standard TaqMan genotyping protocols unless otherwise noted (ABI assays were Thr4Pro: C_22271506_10, Ser98Thr: C_2716008_1_ and Thr136Ile: C_8804621_1_).

In silico analysis

The schematic of VMAT1 protein sequence (Fig. 5b) was rendered using the TEXtopo package (version 1.4) in the free cross-platform LaTex editor TexMakerX version 2.1 (SVN 1774) for Windows downloaded from http://texmakerx.sourceforge.net. The LaTex program for the rendering (available on request) was compiled within TexMakerX to generate a portable document file (.pdf) that was then imported into Microsoft Powerpoint for labeling of common and rare variant amino acids.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania. Financial support is gratefully acknowledged from National Institutes of Health grants NIH K08MH080372 (FWL), NCRR (UL1 RR 024986), NIMH (P01 MH 42251, R25 MH 6374, and K23 MH 074459), NIDA (R01 DA 016423 and R01 DA 02520), NIDA 026222 & NIDA 031579 and the Phil F. Jenkins Research Fund. Dr. Lohoff declares that he is named as one of the inventors of a patent involving human genetic VMAT1 variants (U.S. Pat. No. 7,736,852). Within the 3-year period prior to submission of the manuscript, Dr. Mickey has received salary support from St. Jude Medical for research unrelated to this manuscript, and Dr. Zubieta has served as a paid consultant for Eli Lilly & Co., Johnson & Johnson, Merck, and Abbott for work unrelated to this manuscript.

References

1. Dalgleish T. The emotional brain. Nat Rev Neurosci. 2004; 5:583–589. [PubMed: 15208700]
2. Bouchard TJ Jr, McGue M. Genetic and environmental influences on human psychological differences. J Neurobiol. 2003; 54:4–45. [PubMed: 12486697]

Mol Psychiatry. Author manuscript; available in PMC 2015 January 30.
3. Bevilacqua L, Goldman D. Genetics of emotion. Trends Cogn Sci. 2011; 15:401–408. [PubMed: 21835681]
4. Liu Y, et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell. 1992; 70:539–551. [PubMed: 1505023]
5. Peter D, et al. Chromosomal localization of the human vesicular amine transporter genes. Genomics. 1993; 18:720–723. [PubMed: 7905859]
6. Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proceedings of the National Academy of Sciences of the United States of America. 1996; 93:5166–5171. [PubMed: 8643547]
7. Peter D, et al. Differential expression of two vesicular monoamine transporters. J Neurosci. 1995; 15:6179–6188. [PubMed: 7666200]
8. Ibanez-Sandoval O, et al. Electrophysiological and morphological characteristics and synaptic connectivity of tyrosine hydroxylase-expressing neurons in adult mouse striatum. J Neurosci. 2010; 30:6999–7016. [PubMed: 20484642]
9. Ashe KM, et al. Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain. Neuro Endocrinol Lett. 2011; 32:253–258. [PubMed: 21712771]
10. Hansson SR, Hoffman BJ, Mezye E. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system. Brain Res Dev Brain Res. 1998; 110:135–158. [PubMed: 9733951]
11. Brunk I, et al. The First Luminal Domain of Vesicular Monoamine Transporters Mediates G-protein-dependent Regulation of Transmitter Uptake. The Journal of biological chemistry. 2006; 281:33373–33385. [PubMed: 16926160]
12. Schildkraut JJ, Kety SS. Biogenic amines and emotion. Science (New York, N Y. 1967; 156:21–37.
13. Goodwin FK, Bunney WE Jr. Depressions following reserpine: a reevaluation. Seminars in psychiatry. 1971; 3:435–448. [PubMed: 4154501]
14. Bant WP. Antihypertensive drugs and depression: a reappraisal. Psychological medicine. 1978; 8:275–283. [PubMed: 26094]
15. Widmer RB. Reserpine: the maligned antihypertensive drug. The Journal of family practice. 1985; 20:81–83. [PubMed: 3965606]
16. Wang YM, et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron. 1997; 19:1285–1296. [PubMed: 9427251]
17. Takahashi N, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94:9938–9943. [PubMed: 9275230]
18. Fon EA, et al. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron. 1997; 19:1271–1283. [PubMed: 9427250]
19. Fumagalli F, et al. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci. 1999; 19:2424–2431. [PubMed: 10087057]
20. Narboux-Neme N, et al. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences. Neuropsychopharmacology. 2011; 36:2538–2550. [PubMed: 2181481]
21. Taylor T N, Caudle W M, Miller G W. VMAT2-Deficient Mice Display Nigral and Extracellular Pathology and Motor and Nonmotor Symptoms of Parkinson’s Disease. Parkinsons Dis. 2011; 2011:124165. [PubMed: 21403896]
22. Fukui M, et al. Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci. 2007; 27:10520–10529. [PubMed: 17898223]
23. Richards M, et al. Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population. Behav Brain Funct. 2006; 2:39. [PubMed: 17134514]
24. Bly M. Mutation in the vesicular monoamine gene, SLC18A1, associated with schizophrenia. Schizophrenia research. 2005; 78:337–338. [PubMed: 15961286]
25. Chen SF, et al. Support for association of the A277C single nucleotide polymorphism in human vesicular monoamine transporter 1 gene with schizophrenia. Schizophrenia research. 2007; 90:363–365. [PubMed: 17223313]

26. Lohoff FW, et al. Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia. Neuropsychobiology. 2008; 57:55–60. [PubMed: 18451639]

27. Lohoff FW, et al. Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder. Neuropsychopharmacology. 2006; 31:2739–2747. [PubMed: 16936705]

28. Need AC, et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet. 2009; 17:946–957. [PubMed: 19156168]

29. Lohoff FW, et al. Association between variation in the vesicular monoamine transporter 1 gene on chromosome 8p and anxiety-related personality traits. Neuroscience letters. 2008; 434:41–45. [PubMed: 18249496]

30. Green EK, et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Molecular psychiatry. 2010; 15:1016–1022. [PubMed: 19621016]

31. Craddock N, O’Donovan MC, Owen MJ. Genes for Schizophrenia and Bipolar Disorder? Implications for Psychiatric Nosology. Schizophrenia bulletin. 2005

32. Craddock N, Owen MJ. The Kraepelinian dichotomy - going, going... but still not gone. Br J Psychiatry. 2010; 196:92–95. [PubMed: 20118450]

33. Mickey BJ, et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Archives of general psychiatry. 2011; 68:158–166. [PubMed: 21300944]

34. Bevilacqua L, et al. A population-specific HTR2B stop codon predisposes to severe impulsivity. Nature. 2010; 468:1061–1066. [PubMed: 21179162]

35. Altschuler L, et al. Increased amygdala activation during mania: a functional magnetic resonance imaging study. The American journal of psychiatry. 2005; 162:1211–1213. [PubMed: 15930074]

36. Milad MR, et al. Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biological psychiatry. 2009; 66:1075–1082. [PubMed: 19748076]

37. Costafranca SG, Brammer MJ, David AS, Fu CH. Predictors of amygdala activation during the processing of emotional stimuli: a meta-analysis of 385 PET and fMRI studies. Brain research reviews. 2008; 58:57–70. [PubMed: 18076995]

38. Kim MJ, Gee DG, Loucks RA, Davis FC, Whalen PJ. Anxiety dissociates dorsal and ventral medial prefrontal cortex functional connectivity with the amygdala at rest. Cereb Cortex. 2011; 21:1667–1673. [PubMed: 21127016]

39. Likhtik E, Pelletier JG, Paz R, Pare D. Prefrontal control of the amygdala. J Neurosci. 2005; 25:7429–7437. [PubMed: 16093394]

40. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. The American journal of psychiatry. 2010; 167:509–527. [PubMed: 20231323]

41. Buckholtz JW, et al. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Molecular psychiatry. 2008; 13:313–324. [PubMed: 17519928]

42. Lawrence NS, et al. Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biological psychiatry. 2004; 55:578–587. [PubMed: 15013826]

43. Bora E, Yucel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophrenia bulletin. 2010; 36:36–42. [PubMed: 19776206]

44. Jabben N, Arts B, van Os J, Krabbendam L. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder. The Journal of clinical psychiatry. 2010; 71:764–774. [PubMed: 20122370]
45. Shyn SI, et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Molecular psychiatry. 2009

46. Pinheiro AP, et al. Association study of 182 candidate genes in anorexia nervosa. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B:1070–1080. [PubMed: 20468064]

47. Braff DL, Greenwood TA, Swerdlow NR, Light GA, Schork NJ. Advances in endophenotyping schizophrenia. World Psychiatry. 2008; 7:11–18. [PubMed: 18458787]

48. Gottesman II, Gould TD. Increased amygdala activation during mania: a functional magnetic resonance imaging study. The American journal of psychiatry. 2003; 160:636–645. [PubMed: 12668349]

49. Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1992; 89:10993–10997. [PubMed: 1438304]

50. Essand M, et al. Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1. J Mol Endocrinol. 2005; 35:489–501. [PubMed: 1636835]

51. Hsu DT, Langenecker SA, Kennedy SE, Zubieta JK, Heitzeg MM. fMRI BOLD responses to negative stimuli in the prefrontal cortex are dependent on levels of recent negative life stress in major depressive disorder. Psychiatry research, 2010; 183:202–208. [PubMed: 20685091]

52. Heitzeg MM, Nigg JT, Yau WY, Zubieta JK, Zucker RA. Affective circuitry and risk for alcoholism in late adolescence: differences in frontostriatal responses between vulnerable and resilient children of alcoholic parents. Alcohol Clin Exp Res. 2008; 32:414–426. [PubMed: 18302724]

53. Bradley, MM.; Lang, PJ. The Center for Research in Psychophysiology. University of Florida; Gainesville, FL: 1999. Affective norms for English words (ANEW): Stimuli, instruction manual and affective ratings.

54. Kraemer, HC.; Thiemann, S. How Many Subjects? Statistical Power Analysis in Research. Sage Publications; Newbury Park: 1987.

55. Lancaster JL, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000; 10:120–131. [PubMed: 10912591]

56. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuro Image. 2003; 19:1233–1239. [PubMed: 12880848]

57. Bogdan R, Hyde LW, Hariri AR. A neurogenetics approach to understanding individual differences in brain, behavior, and risk for psychopathology. Molecular psychiatry. 2012

58. Whitfield-Gabrieli S, et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:1279–1284. [PubMed: 19164577]

59. Tzourio-Mazoyer N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuro Image. 2002; 15:273–289. [PubMed: 11771995]
Figure 1. Common human VMAT1 variants and haplotypes used for transfection of CV-1 cell lines

(a) VMAT1 is expressed in human brain: Full length VMAT1 cDNA amplified from human substantia nigra (VMAT1). NTC, no-template control; 100 bp, NEB 100 bp ladder; ΦX174, ΦX174 DNA - Hae III digest marker; λ, bacteriophage λ DNA- Hind III digest marker.

(b) Transfected CV-1 cell lines express VMAT1 protein: Immunoblot showing expression of human VMAT1 variants (136Ile, 98Ser, 4Pro, 136Thr) in VMAT1 stable transfected, but not control (FRT; empty vector transfected) CV-1 cells. β-actin is shown as a loading control.

(c) Pharmacological characterization showing 5-HT uptake by VMAT1 construct is inhibited by reserpine (RES; VMAT1 and VMAT2 inhibitor) but not tetrabenazine (TBZ; VMAT2 only inhibitor). Uptake of [3H]5-HT in digitonin permeabilized CV-1 cells expressing Thr-Thr-Ile isoform of VMAT1 in the presence of RES and TZB. Top x-axis reflects concentration of TZB (μM) while bottom x-axis reflects RES concentration (μM). [3H]5-HT uptake values presented are blanked against uptake by CV-1 cells transfected with empty pcDNA5/FRT vector.

(d) Common VMAT1 SNPs and the haplotypes they form, minor allele frequencies (MAF) are shown for European Americans.
Figure 2. The haplotype containing Thr136Ile increases monoamine transport in vitro

The haplotype containing the common variant Thr136Ile leads to increased monoamine uptake. Common VMAT1 haplotypes were assayed for uptake of $[^3]$H-labeled monoamines (norepinephrine, NE; dopamine, DA; or serotonin, 5HT). The mean±S.E.M. for each assayed construct is shown. ANOVA with Tukey’s HSD post-hoc analysis; ** p<0.01; ***p<0.001
Figure 3. Effect of VMAT1 Thr136Ile genotype on medial prefrontal cortex (PFC) responses to negative words

(a) Task effect (negative–neutral word contrast) in the medial PFC for healthy participants is shown in 3 sections: sagittal at x=−2 (left), coronal at y=56 (upper right), and horizontal at z=22 (lower right). Blue area indicates uncorrected 2-sided P<0.001. L indicates left; R, right. This cluster was extracted as a region of interest to test for the effect of VMAT1 genotype.

(b) Effect of VMAT1 genotype on percent signal change in the medial PFC region of interest shown in A (p=0.008). Error bars indicate standard error of the mean.

(c) Exploratory analysis of gene effects elsewhere in the brain. Effect of VMAT1 genotype (Thr homozygotes vs Ile carriers) is shown in 3 sections: sagittal at x=−4 (left), coronal at y=58 (upper right), and horizontal at z=20 (lower right). Scale bar represents uncorrected P value and F statistic.
Figure 4. Genetic variation in human VMAT1 is associated with threat-related amygdala reactivity

(a) Bilateral threat-related amygdala reactivity across all participants. Right hemisphere MNI coordinates = 28, -4, -20 (t = 25.59, p < .01), cluster size=218 voxels. Left hemisphere MNI coordinates= -22, -6, -18 (t = 24.80, p < .01), cluster size=170 voxels.

(b) A allele carriers (136Ile) (n = 121) had increased left amygdala reactivity relative to G homozygotes (136Thr) (n = 177).
Figure 5. Common and rare VMAT1 variants detected by sequencing
(a) Predicted topology of full length human VMAT1 protein showing twelve transmembrane domains and clustering of variation in the first intra-vesicular loop, * indicates common variant MAF >20%.
(b) Comparison of amino acid sequences from different species indicates strong conservation at positions of common and rare variants. Rare variants highlighted in red.
Figure 6. The rare VMAT1 variant Phe84Ser and Arg138Leu lead to increased and decreased dopamine (DA) uptake in vitro respectively.

(a) Phe84Ser dopamine uptake in vitro

(b) Arg138Leu dopamine uptake in vitro

Data are expressed as the mean ± S.E.M. The Student’s t test was used to compare monoamine uptake for rare variants. **p<0.01, ***p<0.001
Case-Control study of rare functional non-synonymous SNPs in VMAT1

The functional amino acid polymorphisms Phe84Ser and Arg138Leu were genotyped in 4023 BPD cases and 3305 controls of European descent using standard ABI Taqman “assay by design” genotyping methods. DNA samples were obtained from the NIMH genetics initiative. Results show that the Ser84 allele was absent in controls but present in 7 BPD individuals, one homozygote and 6 heterozygotes (Fisher exact test). The Arg138Leu variant frequency did not differ statistically significant between cases and controls.

|     | Bipolar | Controls | p value |
|-----|---------|----------|---------|
| F84S |         |          |         |
| Phe84 allele | 7846 | 6610 | 0.009  |
| Ser84 allele  | 8    | 0      |         |
| R138L |         |          |         |
| Arg138 allele | 8039 | 6586 | 0.199  |
| Leu138 allele  | 7    | 2      |         |